Journal article

Outcomes of Older Patients (>= 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20

J Connor Wells, Dongsheng Tu, Lillian L Siu, Jeremy D Shapiro, Derek J Jonker, Christos Karapetis, John Simes, Geoffrey Liu, Timothy J Price, Niall C Tebbutt, Chris J O'Callaghan

CLINICAL COLORECTAL CANCER | CIG MEDIA GROUP, LP | Published : 2019

Abstract

BACKGROUND: The safety and efficacy of targeted therapy in older patients (≥ 70 years) with metastatic colorectal cancer is not well evaluated. PATIENTS AND METHODS: Outcomes of older patients (including overall survival [OS], progression-free survival [PFS], toxicity, and quality of life [QoL]) were compared to young patients using data from 2 large previously reported clinical trials, CO.17 (cetuximab vs. best supportive care) and CO.20 (cetuximab plus placebo vs. cetuximab plus brivanib). Only patients with wild-type KRAS tumors were included. RESULTS: A total of 251 (26.3%) of 955 patients were ≥ 70 years old. No significant differences in OS, PFS, or grade 3/4 adverse events were observ..

View full abstract

University of Melbourne Researchers